In tackling resistance to EGFR-TKI in lung cancer, Manoalide has been shown to effectively enhance the sensitivity of lung cancer cells to osimertinib by inhibiting the NRF2-SLC7A11 axis and inducing ferroptosis by down-regulation of ferritin heavy chain 1 through mitochondrial Ca2+ overload (64). Here, SLC7A11 is linked to lung cancer.